Efficacy and Pharmacokinetics/Pharmacodynamics of TP-271 vs Acinetobacter Baumannii

StatusFinished
Effective start/end date11/09/1531/05/16

Funding

  • Tetraphase Pharmaceuticals Inc.: $135,795.75

Keywords

  • Infectious Diseases